| Dissertation note |
The present study was carried to investigate the hematological alterations in the patients diagnosed as cancer and were administered vinorelbine as part of their chemotherapy at Shoukat khanum memorial cancer hospital and research centre. It was carried in the chemotherapy department, pathology laboratory, medical record section, pharmacy department, and data processing department of the hospital. For investigating there were a total of 60 adult cancer patients with non-small cell lung cancer (NSCL), metastatic breast cancer (MBC), and cancer of cervix (CC), with age between 24 to 71 years (Mean±SEM: 42.73±2.69) selected. Which were divided into two groups: Group - I for those patients who were on the treatment protocol of Vinorelbine alone (25 mg/m2/day one, weekly x 4) and group - II for those patients who were on treatment protocol of Vinorelbine base combinations Vinorelbine/Doxorubicin (Vinorelbine - 20 mg/m2/day one and day eight, Doxorubicin - 50 mg/m2/day one only) and Vinorelbine/Cisplatin (Vinorelbine - 20 mg/m2/day one and day eight, Cisplatin - 40 mg/m2/day one only). The Laboratory tests (C.B.C.) of all the patients were performed in the Pathology Laboratory of the hospital. After completion of the study, the collected Hematological values were statistically analyzed by student pair test. By the overall comparison of mean values over time, there were significant leukopenia (neutrophile, eosinophil, & monocyte), anemia and decreased hematocrit value observed in the patients on chemotherapy protocol of Vinorelbine alone and significant leukopenia (neutrophile only), anemia and decreased hematocrit value and hemoglobine conc. observed in the patients on chemotherapy protocol of Vinorelbine based combinations. By an independent comparison of mean values of two groups at every week, there were significantly higher toxicities 1 e leukopenia at week-3 (neutrohpil at week-3, eosinophil at weekI, lymphocyte at week-i &2) and thrombocytopenia at week-i observed in the patients on the treatment protocol of Vinorelbine based combinations. When the mean values observed before therapy were compared with that of at week-4 of both of the groups, there were significant decreases noted in TLC, neutrophil count, monocyte count, erythrocyte count, hemotocrit value and Hb conc in the patients on treatment protocol of Vinorelbine alone, and erythrocyte count, hemotocrit value and hemoglobine conc. in the patients on treatment protocol of Vinorelbine based combinations. It is concluded from this study that, there is insignificant difference in the overall hematological toxicities produced by both of the chemotherapy protocols. The clinical oncologist, consultant physicians and pharmacist, therefore now suggested to select the either of the of the chemotherapy protocol with respect of the therapeutic efficacy only
|
